BMRN
BIOMARIN PHARMACEUTICAL INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 ▼ 2 insiders sell $2.0M at $61.17
- Mar 11 ▼ 1 insider sell $996.7K at $60.46
- Mar 26 Ascendis Pharma A/S v. Biomarin Pharmaceutical Inc.
- Apr 27 ▲ Biogen completed its acquisition of Amicus Therapeutics for $4.8 bil…
- May 7 ▼ 1 insider sell $176.7K at $53.85
- Jul 17 Trial readout: Results Pending: Valoctocogene roxaparvovec (Phase 2), Com…
- Aug 18 ▲ BioMarin (BMRN) entered into a definitive Share Purchase Agreement t…
- Aug 19 BMO Capital initiates
- Aug 31 ▲ BioMarin entered a binding term sheet with Ascendis Pharma to settle…
- Sep 2 ▼ 1 insider sell $1.2M at $66.28
- Oct 6 ▼ BioMarin disclosed that its Q3 2026 results will include ~$283M in p…
- Nov 2 ▼ BioMarin reported Q3 2026 total revenues of $1.025B, up 32% YoY, dri…
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $4.3M.
- InstitutionsMIXED
Q3 2026: 37 added (2 new), 41 trimmed or exited. Largest new: Barrow Hanley Mewhinney & Strauss $10.8M.
- AnalystsBULLISH
27 of 35 rate it Buy or better.
- Short sellersBUILDING
Short interest +17.2% to 14.12M shares. 5.8 days to cover, ≈7.3% of shares.
- TrendRANGE
1% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $440.6M |
| UBS Group AG | ADD | $108.4M |
| JPMORGAN CHASE & CO | ADD | $63.5M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $43.7M |
| MACKENZIE FINANCIAL CORP | TRIM | $33.9M |
| LOOMIS SAYLES & CO L P | TRIM | $25.6M |
| BARCLAYS PLC | ADD | $20.3M |
| Amundi | ADD | $20.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
35 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Nov 4, 2026 | JP Morgan MAINTAIN | Overweight |
| Nov 3, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Nov 3, 2026 | Oppenheimer MAINTAIN | Outperform |
| Nov 3, 2026 | HC Wainwright & Co. REITERATE | Neutral |
| Nov 3, 2026 | RBC Capital MAINTAIN | Sector Perform |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Friberg Gregory R EVP, Chief R&D Officer Sep 30, 2026 | TAX W/H | $245.2K |
Plenge Robert M Director Sep 10, 2026 | AWARD | 6,140 sh |
Davis George Eric EVP, Chief Legal Officer Sep 2, 2026 | SELL | $1.2M |
Ho Maykin Director Jun 2, 2026 | AWARD | 7,490 sh |
ANDERSON ELIZABETH M Director Jun 2, 2026 | AWARD | 7,490 sh |
CLARK IAN T Director Jun 2, 2026 | AWARD | 7,490 sh |
Bodem Barbara W. Director Jun 2, 2026 | AWARD | 7,490 sh |
Dere Willard H Director Jun 2, 2026 | AWARD | 7,490 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
15 filings · 1 press release · 3 bullish · 2 bearish · 2 mixed · 8 neutral- NEUTRAL SC 13G/ANov 4, 2026
BlackRock filed an amended Schedule 13G disclosing beneficial ownership of 19,373,309 shares of…
BlackRock's passive stake increase to 10.0% is consistent with index fund rebalancing and does not signal activist intent. Monitor for any conversion to a 13D filing if BlackRock engages with…
- BEARISH 8-KNov 2, 2026
BioMarin reported Q3 2026 total revenues of $1.025B, up 32% YoY, driven by the Amicus acquisition…
The massive Non-GAAP EPS guidance cut (from ~$5.00 to ~$2.95) overshadows the 32% revenue beat. The shift of a large VOXZOGO international order from Q3 to Q4 and the order timing uncertainty cited…
- NEUTRAL INST-CLUSTEROct 29, 2026
Three small asset managers added to their BMRN positions in Q3 2026, while one larger…
The cluster shows no strong conviction signal: buying is trivial in scale and from small advisors, while the sole meaningful seller reduced by a material amount. Monitor the upcoming Q3 earnings…
- MIXED INST-CLUSTEROct 27, 2026
In Q2 2026, institutional activity in BioMarin was mixed: 43 buyers added $165.7M in positions…
The divergence between passive accumulation and active/quant selling suggests institutional uncertainty about near-term fundamentals. Monitor Q3 2026 earnings (expected late Oct/early Nov) for…
All BMRN filing & press-release reports (16)
- SC 13G/A reportNov 4, 2026
- 8-K reportNov 2, 2026
- INST-CLUSTER reportOct 29, 2026
- INST-CLUSTER reportOct 27, 2026
- 8-K reportOct 6, 2026
- 8-K reportSep 15, 2026
- 8-K reportSep 14, 2026
- 8-K reportSep 1, 2026
- PRESS-RELEASE reportSep 1, 2026
- 8-K reportAug 31, 2026
- 8-K reportAug 18, 2026
- 8-K reportJun 4, 2026
- 8-K reportApr 27, 2026
- DEFA14A reportApr 21, 2026
- INST-CLUSTER reportFeb 28, 2026
- CLUSTER reportFeb 26, 2026